نتایج جستجو برای: etanercept

تعداد نتایج: 3313  

2018
Kyle J. Brymer Erin Y. Fenton Lisa E. Kalynchuk Hector J. Caruncho

Depression is a serious psychiatric disorder frequently comorbid with autoimmune disorders. Previous work in our lab has demonstrated that repeated corticosterone (CORT) injections in rats reliably increase depressive-like behavior, impair hippocampal-dependent memory, reduce the number and complexity of adult-generated neurons in the dentate gyrus, decrease hippocampal reelin expression, and a...

2008
H Schmeling G Horneff

Results A total of 33 patients initially treated with Etanercept were switched to Adalimumab after a mean of 25.9 months (range 3–87 months). Reasons for discontinuation of Etanercept were inefficacy (n = 23, 65.8%), uveitis (n = 6, 17.1%), intolerance (n = 3, 8.6%) and patients' request (n = 6, 17.1%). Follow up data on Adalimumab were obtained from 12 patients for a range of 2 to 26 months (m...

Journal: :Annals of the rheumatic diseases 2005
M Rudwaleit X Baraliakos J Listing J Brandt J Sieper J Braun

OBJECTIVE To assess the changes in inflammatory lesions of the spine and the sacroiliac (SI) joints as detected by magnetic resonance imaging (MRI) in patients with ankylosing spondylitis (AS) and undifferentiated spondyloarthritis (uSpA) with predominant axial symptoms during treatment with etanercept. METHODS MRI of the spine and/or the SI joints of patients with active AS or axial uSpA was...

2014
Joo Han Park Hyo Jung Lee Sei Rhan Kim Ga Won Song Seung Kyong Lee Sun Young Park Ki Chan Kim Sun Hyuk Hwang Joon Seong Park

BACKGROUND/AIMS The treatment for steroid-refractory acute graft versus host disease (GVHD) after allogeneic stem cell transplantation (allo-SCT) needs to be standardized. We report our clinical experience with etanercept for steroid-refractory acute GVHD. METHODS Eighteen patients who underwent allo-SCT and presented with steroid-refractory acute GVHD at Ajou University Hospital were studied...

Journal: :Chest 2003
James P Utz Andrew H Limper Sanjay Kalra Ulrich Specks John P Scott Zvezdana Vuk-Pavlovic Darrell R Schroeder

BACKGROUND Tumor necrosis factor (TNF)-alpha is produced by macrophages and other cells, and is believed to participate in granulomatous inflammation. Targeted antagonism of TNF-alpha has been proposed as a novel treatment strategy for sarcoidosis. Etanercept is a dimeric fusion protein that binds specifically to TNF-alpha, rendering it biologically inactive. OBJECTIVE To assess whether etane...

2009
Amu Kawaguchi Hiroyuki Nakaya Takahiro Okabe Keiji Tensho Masashi Nawata Yoshitaka Eguchi Yuuki Imai Kunio Takaoka Shigeyuki Wakitani

BACKGROUND AND PURPOSE Osteochondral defects have a limited capacity for repair. We therefore investigated the effects of tumor necrosis factor (TNF) signal blockade by etanercept (human recombinant soluble TNF receptor) on the repair of osteochondral defects in rabbit knees. MATERIAL AND METHODS Osteochondral defects (5 mm in diameter) were created in the femoral patellar groove in rabbits. ...

2009
Siegfried Segaert

Etanercept, a subcutaneously administered fully human soluble tumor necrosis factor (TNF) receptor, was initially approved for the treatment of psoriasis at a dose of 25 mg twice weekly in repeated 24-week cycles with the possibility to double the dose in the first 12 weeks of the first cycle. During intermittent treatment, patients retain their ability to respond to etanercept. Recently, a new...

2012
Olof Sandberg Pernilla Eliasson Therese Andersson Fredik Agholme Per Aspenberg

BACKGROUND AND PURPOSE Should blockade of TNF-α be avoided after orthopedic surgery? Healing of injuries in soft tissues and bone starts with a brief inflammatory phase. Modulation of inflammatory signaling might therefore interfere with healing. For example, Cox inhibitors impair healing in animal models of tendon, ligament, and bone injury, as well as in fracture patients. TNF-α is expressed ...

Journal: :Rheumatology 2012
Helena Canhão Ana Maria Rodrigues Ana Filipa Mourão Fernando Martins Maria José Santos José Canas-Silva Joaquim Polido-Pereira José Alberto Pereira Silva José António Costa Domingos Araújo Cândida Silva Helena Santos Cátia Duarte José Antonio Pereira da Silva Fernando M Pimentel-Santos Jaime Cunha Branco Elizabeth W Karlson João Eurico Fonseca Daniel H Solomon

OBJECTIVES Adalimumab, etanercept and infliximab are effective TNF inhibitors (TNFis) in the treatment of RA, but no randomized clinical trials have compared the three agents. Prior observational data are not consistent. We compared their effectiveness over 1 year in a prospective cohort. METHODS Analyses were performed on subjects' first episode of TNFi use in the Rheumatic Diseases Portugue...

Journal: :Rheumatology International 2014

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید